U.S. Sen. Richard Blumenthal pressed Markwayne Mullin, the nominee to lead the U.S. Department of Homeland Security, on ...

A 24-year old Mexican man sought by federal immigration officers was not in the South Burlington house that authorities raided last night, the U.S. attorney's office said. None of the three people ...

A NASA satellite that spent more than a decade coursing through the Van Allen radiation belts encircling Earth is about to fall back into the atmosphere. Most of the spacecraft will burn up during ...

TEL AVIV - Entera Bio Ltd. (NASDAQ:ENTX) submitted a clinical amendment to the U.S. Food and Drug Administration for its Phase 3 protocol of EB613, an oral tablet treatment for osteoporosis, according ...

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 ...

Secret Service agents and a Palm Beach sheriff's deputy fatally shot a man carrying a shotgun and a gas canister as he tried to enter the Mar-a-Lago club owned by President Donald Trump. Trump, who ...

The president brushed aside the norms of international diplomacy when he targeted narcoterrorists, fought with European allies and bombed Iran. As part of our video series on Trump’s second term, The ...

TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced ...

(RTTNews) - Entera Bio Ltd. (ENTX) has appointed Geno J. Germano, a veteran biopharmaceutical leader with senior roles at Pfizer, Wyeth and Intrexon, as Chairman of its Board of Directors. His ...

New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant ...

Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral ...

The additional program combines OPKO's proprietary long-acting PTH variants with Entera's proprietary N-Tab® technology. Following favorable pharmacodynamic and pharmacokinetic (PK/PD) data reported ...